Knee Osteoarthritis Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032), States DelveInsight | Novartis, Biosplice Therapeutic, Sorrento Therapeutic, Eli Lilly

Posted on
by

Knee Osteoarthritis Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032), States DelveInsight | Novartis, Biosplice Therapeutic, Sorrento Therapeutic, Eli Lilly
“Knee Osteoarthritis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Knee Osteoarthritis, historical and forecasted epidemiology.

DelveInsight’s “Knee Osteoarthritis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Knee Osteoarthritis, historical and forecasted epidemiology as well as the Knee Osteoarthritis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Knee Osteoarthritis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Knee Osteoarthritis Market Forecast

 

Some of the key facts of the Knee Osteoarthritis Market Report: 

  • The Knee Osteoarthritis market size was valued approximately USD 13 billion in 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • Anticipated launch of potential Knee Osteoarthritis therapies by notable companies, including Techfields (X0002), Taiwan Liposome Company (TLC599), Centrexion Therapeutics (CNTX-4975), Biosplice Therapeutics (Lorecivivint), Ampio Pharmaceuticals (Ampion), Paradigm Biopharmaceuticals (Zilosul), Grünenthal (RTX-GRT7039/Resiniferatoxin), Naturecell (JointStem), and other contenders, might contribute to the market’s expansion of Knee Osteoarthritis in the upcoming years, supported by an expected rise in the prevalent population suffering from knee osteoarthritis.
  • In 2021, the total prevalent population diagnosed with symptomatic Knee Osteoarthritis across the seven major markets reached 47,874,567. The United States reported the highest prevalence with 17,660,391 cases, while the combined cases in EU4 and the UK accounted for 19,946,245 cases.
  • According to the assessment, a greater proportion of mild cases of knee Osteoarthritis was identified across the 7 Major Markets (7MM) in 2021, followed by moderate knee Osteoarthritis. In the United States specifically, the highest number of cases in 2021 was reported for mild knee osteoarthritis, with 7,373,858 cases, followed by moderate Knee Osteoarthritis, totaling 6,562,734 cases
  • In the European Union (EU4) and the United Kingdom (UK) in 2021, the most significant percentage of cases was observed in the age group of 70 years and above, followed by the age categories of 60–69 years and 50–59 years. Specifically, there were 638,280, 1,735,323, 4,328,335, 4,807,045, and 8,437,262 cases documented in the age groups of 18–39 years, 40–49 years, 50–59 years, 60–69 years, and 70 years and above, respectively.
  • Key Knee Osteoarthritis Companies: Bioventus LLC, Akan Biosciences, LLC, Genascence Corporation, Immunis, Inc., Novartis, Biosplice Therapeutics, Sorrento Therapeutics, Inc., Novartis, Celltex Therapeutics Corporation, MiMedx Group, Inc., Rho, Inc., Techfields Pharma Co. Ltd, Eli Lilly and Company, Nature Cell Co. Ltd., Novo Nordisk A/S, Flexion Therapeutics, Inc., Grünenthal GmbH, Tissue Tech Inc., Kolon TissueGene, Inc., Saol Therapeutics Inc, Centrexion Therapeutics, Taiwan Liposome Company, MiMedx, Ampio Pharmaceuticals, ReNu, Medipost, and others
  • Key Knee Osteoarthritis Therapies: TP-001, StroMel, GNSC-001, IMM01-STEM, RHH646, Lorecivivint, Resiniferatoxin, DFV890, Celltex- AdMSCs, Micronized DHACM, X0002, Retatrutide, JointStem, Semaglutide, FX201, RTX-GRT7039, TTAX03, TG-C, SL-1002, CNTX-4975, TLC599, Amniofix, Ampion, Organogenesis, Cartistem, and others
  • The Knee Osteoarthritis epidemiology based on gender analyzed that females are most commonly affected than males in case of Knee Osteoarthritis
  • The Knee Osteoarthritis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Knee Osteoarthritis pipeline products will significantly revolutionize the Knee Osteoarthritis market dynamics.

 

Knee Osteoarthritis Overview

Degenerative joint disease, commonly referred to as osteoarthritis of the knee, is usually caused by articular cartilage gradually losing its structure due to wear and tear. It can be separated into two categories, main and secondary, and is most prevalent in the elderly.

 

Get a Free sample for the Knee Osteoarthritis Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/knee-osteoarthritis-market

 

Knee Osteoarthritis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Knee Osteoarthritis Epidemiology Segmentation:

The Knee Osteoarthritis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Knee Osteoarthritis
  • Prevalent Cases of Knee Osteoarthritis by severity
  • Gender-specific Prevalence of Knee Osteoarthritis
  • Diagnosed Cases of Episodic and Chronic Knee Osteoarthritis

 

Download the report to understand which factors are driving Knee Osteoarthritis epidemiology trends @ Knee Osteoarthritis Epidemiology Forecast

 

Knee Osteoarthritis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Knee Osteoarthritis market or expected to get launched during the study period. The analysis covers Knee Osteoarthritis market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Knee Osteoarthritis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Knee Osteoarthritis Therapies and Key Companies

  • Retatrutide: Eli Lilly and Company
  • JointStem: Nature Cell Co. Ltd.
  • Semaglutide: Novo Nordisk A/S
  • FX201: Flexion Therapeutics, Inc.
  • RTX-GRT7039: Grünenthal GmbH
  • TTAX03: Tissue Tech Inc.
  • TG-C: Kolon TissueGene, Inc.
  • SL-1002: Saol Therapeutics Inc
  • PTP-001: Bioventus LLC
  • StroMel: Akan Biosciences, LLC
  • GNSC-001: Genascence Corporation
  • IMM01-STEM: Immunis, Inc.
  • RHH646: Novartis
  • Lorecivivint: Biosplice Therapeutics
  • Resiniferatoxin: Sorrento Therapeutics, Inc.
  • DFV890: Novartis
  • Celltex- AdMSCs: Celltex Therapeutics Corporation
  • Micronized DHACM: MiMedx Group, Inc./Rho, Inc.
  • X0002: Techfields Pharma Co. Ltd
  • CNTX-4975: Centrexion Therapeutics
  • TLC599: Taiwan Liposome Company
  • Amniofix: MiMedx
  • Ampion: Ampio Pharmaceuticals
  • Organogenesis: ReNu
  • Cartistem: Medipost

 

Discover more about therapies set to grab major Knee Osteoarthritis market share @ Knee Osteoarthritis Treatment Landscape

 

Knee Osteoarthritis Market Strengths

  • Now companies are investing heavily in developing disease modifying therapies for the treatment of knee osteoarthritis, which will fulfill a major unmet need.
  • Many key players are developing cell therapies for knee osteoarthritis, which are in various stages of development. These therapies, if approved, may provide better treatment options as it can slow disease progression and may possibly cure the disease.

 

Knee Osteoarthritis Market Opportunities

For the treatment of Knee OA, usage of opioids can be seen. The majority of patients/ physicians are eagerly waiting for nonopioids options and key players can target this lucrative segment of the market, while others are already developing therapies for the same.

 

Scope of the Knee Osteoarthritis Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Knee Osteoarthritis Companies: Bioventus LLC, Akan Biosciences, LLC, Genascence Corporation, Immunis, Inc., Novartis, Biosplice Therapeutics, Sorrento Therapeutics, Inc., Novartis, Celltex Therapeutics Corporation, MiMedx Group, Inc., Rho, Inc., Techfields Pharma Co. Ltd, Eli Lilly and Company, Nature Cell Co. Ltd., Novo Nordisk A/S, Flexion Therapeutics, Inc., Grünenthal GmbH, Tissue Tech Inc., Kolon TissueGene, Inc., Saol Therapeutics Inc, Centrexion Therapeutics, Taiwan Liposome Company, MiMedx, Ampio Pharmaceuticals, ReNu, Medipost, and others
  • Key Knee Osteoarthritis Therapies: TP-001, StroMel, GNSC-001, IMM01-STEM, RHH646, Lorecivivint, Resiniferatoxin, DFV890, Celltex- AdMSCs, Micronized DHACM, X0002, Retatrutide, JointStem, Semaglutide, FX201, RTX-GRT7039, TTAX03, TG-C, SL-1002, CNTX-4975, TLC599, Amniofix, Ampion, Organogenesis, Cartistem, and others
  • Knee Osteoarthritis Therapeutic Assessment: Knee Osteoarthritis current marketed and Knee Osteoarthritis emerging therapies
  • Knee Osteoarthritis Market Dynamics: Knee Osteoarthritis market drivers and Knee Osteoarthritis market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Knee Osteoarthritis Unmet Needs, KOL’s views, Analyst’s views, Knee Osteoarthritis Market Access and Reimbursement 

 

To know more about Knee Osteoarthritis companies working in the treatment market, visit @ Knee Osteoarthritis Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Knee Osteoarthritis Market Report Introduction

2. Executive Summary for Knee Osteoarthritis

3. SWOT analysis of Knee Osteoarthritis

4. Knee Osteoarthritis Patient Share (%) Overview at a Glance

5. Knee Osteoarthritis Market Overview at a Glance

6. Knee Osteoarthritis Disease Background and Overview

7. Knee Osteoarthritis Epidemiology and Patient Population

8. Country-Specific Patient Population of Knee Osteoarthritis 

9. Knee Osteoarthritis Current Treatment and Medical Practices

10. Knee Osteoarthritis Unmet Needs

11. Knee Osteoarthritis Emerging Therapies

12. Knee Osteoarthritis Market Outlook

13. Country-Wise Knee Osteoarthritis Market Analysis (2019–2032)

14. Knee Osteoarthritis Market Access and Reimbursement of Therapies

15. Knee Osteoarthritis Market Drivers

16. Knee Osteoarthritis Market Barriers

17.  Knee Osteoarthritis Appendix

18. Knee Osteoarthritis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com